Edluar generic
Edluar is a sleep-aid medication owned by Mylan Specialty LP. The active ingredient in Edluar is zolpidem tartrate. The drug was first authorized for market use on March 13, 2009. It is available in a sublingual tablet dosage form and is used predominantly for the treatment of insomnia characterized by difficulty with sleep onset.
When will Edluar generic be available?
The generic version of Edluar is expected to become available after February 25, 2031. This date corresponds to the expiration of the last patent held by Mylan Specialty LP. Specifically, the patent (US9265720) titled 'Pharmaceutical formulations useful in the treatment of insomnia' expires on this date.
Edluar uses
Edluar is commonly used as a treatment for insomnia, particularly in cases characterized by difficulty with sleep onset. The active ingredient, zolpidem tartrate, works by slowing brain activity, helping the user to fall asleep faster and enjoy a restful night's sleep.
Edluar patent expiration
Edluar holds two patents, with the last expiring on February 25, 2031. This patent, US9265720, is titled 'Pharmaceutical formulations useful in the treatment of insomnia.' The availability of Edluar generic will therefore be possible after this date. Below are the details of the patent: